Skip to main content
padlock icon - secure page this page is secure

Structure of RiVax: a recombinant ricin vaccine

Buy Article:

$47.00 + tax (Refund Policy)

RiVax is a recombinant protein that is currently under clinical development as part of a human vaccine to protect against ricin poisoning. RiVax includes ricin A‐chain (RTA) residues 1–267 with two intentional amino‐acid substitutions, V76M and Y80A, aimed at reducing toxicity. Here, the crystal structure of RiVax was solved to 2.1 Å resolution and it was shown that it is superposable with that of the ricin toxin A‐chain from Ricinus communis with a root‐mean‐square deviation of 0.6 Å over 258 Cα atoms. The RiVax structure is also compared with the recently determined structure of another potential ricin‐vaccine immunogen, RTA 1–33/44–198 R48C/T77C. Finally, the locations and solvent‐exposure of two toxin‐neutralizing B‐cell epitopes were examined and it was found that these epitopes are within or near regions predicted to be involved in catalysis. The results demonstrate the composition of the RiVax clinical material and will guide ongoing protein‐engineering strategies to develop improved immunogens.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Publication date: 01 September 2011

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more